Certara, Inc.
A maker of biosimulation software that lets drug developers test medicines in virtual patients before real trials, Certara's tools include Simcyp, Phoenix, and Chemaxon, and are used by researchers and regulators around the world. It was formed in 2008 from the merger of Tripos and Pharsight, two pioneers in molecular modeling and clinical trial simulation. The coined name "Certara" echoes the word certainty — a nod to its aim of making drug development more predictable.
Granted 237.7K · Bought 24.1K · Sold 910.0K
Sold 2.08M
Granted 13.3K · Bought 25.0K · Sold 200.0K
Granted 45.4K · Sold 45.0K
Sold 45.0K
Granted 122.1K · Sold 60.3K
Sold 54.5K
Sold 72.5K
Granted 45.4K · Sold 12.1K
Granted 30.7K · Sold 181.0K
Granted 122.1K · Sold 256.1K
Granted 143.7K
Granted 59.8K
Granted 45.4K
Granted 45.4K
Granted 45.7K · Bought 5.0K
Granted 35.9K · Sold 69.7K
Granted 45.7K
Bought 20.0K
Granted 56.5K
Granted 26.5K
Granted 18.8K
Granted 24.1K
Granted 17.6K
Granted 10.8K
Granted 5.5K
Sold 58.97M
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Feehery William FCHIEF EXECUTIVE OFFICER, Director · 36 transactions | -23.6% | 2.36M | 237.7K | 24.1K | 910.0K |
| Slaine Mason PDirector · 16 transactions | -75.9% | 660.3Kas of Nov 2022 | — | — | 2.08M |
| Schemick Michael AndrewCHIEF FINANCIAL OFFICER · 11 transactions | -26.4% | 514.1Kas of Mar 2023 | 13.3K | 25.0K | 200.0K |
| Cashman James E IIIDirector, Chairman · 6 transactions | +0.1% | 484.2K | 45.4K | — | 45.0K |
| Edge JustinPRES., REGULATORY & ACCESS · 9 transactions | -10.7% | 394.8Kas of Apr 2022 | — | — | 45.0K |
| Aspbury RobertPRESIDENT, PREDICTIVE TECH · 38 transactions | -5.2% | 321.7K | 122.1K | — | 60.3K |
| Rayner Craig R.PRESIDENT, INTEGRATED DRUG DEV · 4 transactions | -14.8% | 316.0Kas of Sep 2021 | — | — | 54.5K |
| Choe Jieun W.CHIEF STRATEGY & MARKETING · 9 transactions | -23% | 248.6Kas of Apr 2022 | — | — | 72.5K |
| Walsh Matthew MDirector · 5 transactions | +18.5% | 213.3K | 45.4K | — | 12.1K |
| Traynor Richard M.SVP AND GENERAL COUNSEL · 34 transactions | -47.3% | 178.8Kas of Apr 2024 | 30.7K | — | 181.0K |
| Pedersen Leif EPRESIDENT, CHIEF COMMERCAL OFF · 36 transactions | -69.7% | 85.0K | 122.1K | — | 256.1K |
| Gallagher John EChief Financial Officer · 18 transactions | — | 62.1K | 143.7K | — | — |
| Resnick Jon MatthewChief Executive Officer, Director · 2 transactions | — | 59.8K | 59.8K | — | — |
| Collins CynthiaDirector · 4 transactions | +706.2% | 51.8K | 45.4K | — | — |
| Killefer NancyDirector · 4 transactions | +706.2% | 51.8K | 45.4K | — | — |
| Broshy EranDirector, Chairman · 6 transactions | — | 50.7K | 45.7K | 5.0K | — |
| Smith Patrick FPRESIDENT, DRUG DEV SOLUTIONS · 26 transactions | — | 50.1Kas of Oct 2024 | 35.9K | — | 69.7K |
| Crane Rosemary ADirector · 4 transactions | — | 45.7K | 45.7K | — | — |
| McLean Stephen M.Director · 1 transaction | +90.9% | 42.0Kas of Aug 2022 | — | 20.0K | — |
| Corcoran DanielSVP and General Counsel · 10 transactions | — | 39.9K | 56.5K | — | — |
| Reynders John V WChief Financial Officer, Director · 2 transactions | — | 26.5K | 26.5K | — | — |
| Sherman Nicolette DCHIEF HUMAN RESOURCES OFFICER · 11 transactions | +64.4% | 25.7Kas of Apr 2024 | 18.8K | — | — |
| Anhalt RonaChief Human Resources Officer · 6 transactions | — | 19.0K | 24.1K | — | — |
| Virkler DraytonPRESIDENT, REG & ACCES · 5 transactions | — | 12.4Kas of Mar 2023 | 17.6K | — | — |
| McKemey AdrianPresident, Drug Dev. Solutions · 2 transactions | — | 8.2K | 10.8K | — | — |
| Bedi ArjunDirector · 1 transaction | — | 5.5K | 5.5K | — | — |
| EQT Avatar Parent GP LLC +2 co-filers10% owner · 5 transactions | -100% | 0as of Dec 2022 | — | — | 58.97M |
Select a row to see that insider’s individual transactions.
Net open-market activity over the last 5 years: -62.88M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.